3D Epigenetic Technology and the EpiSwitch Diagnostic Platform
Oxford BioDynamics Plc (LSE:OBD) has continued the commercial rollout of its proprietary EpiSwitch® 3D genomic biomarker platform across clinical diagnostic and oncology markets. Listed on AIM and a constituent of the FTSE AIM All-Share index, the biotechnology company translates three-dimensional chromosome conformation changes into precision diagnostic blood tests. Unlike standard genomic sequencing that only detects fixed DNA mutations, EpiSwitch analyzes dynamic chromosome looping mechanisms that reflect real-time gene expression, immune system activation, and therapeutic resistance.
Commercial Acceleration of EpiSwitch PSE Prostate Cancer Test
The flagship commercial diagnostic product for Oxford BioDynamics (LSE:OBD) is the EpiSwitch Prostate Screening (PSE) test. Designed to improve upon the notoriously inaccurate PSA blood test, the EpiSwitch PSE test combines traditional PSA measurement with specific epigenetic chromosome conformations, achieving an notable 94% diagnostic accuracy for prostate cancer detection. By dramatically reducing unnecessary, invasive prostate biopsies and identifying aggressive malignancies earlier, the test provides significant clinical Utility for urologists and patients across the US and UK private healthcare sectors.
Clinical Assays for Immunotherapy Response: EpiSwitch CiRT
Complementing its cancer screening products, the company markets the EpiSwitch Checkpoint Inhibitor Response Test (CiRT), a predictive blood test that identifies which cancer patients will benefit from expensive immune checkpoint inhibitor therapies (such as Keytruda and Opdivo). CiRT provides oncologists with critical therapeutic guidance, preventing non-responsive patients from undergoing toxic, ineffective treatments and saving healthcare payors tens of thousands of pounds per patient in unneeded drug expenditures.
Capital Position, Commercial Test Adoption, and Cash Runway
From a financial perspective, Oxford BioDynamics (LSE:OBD) is executing an intensive commercialization strategy, transitioning from R&D expenditures toward clinical testing Revenue generation. In its statutory financial accounts, the company recorded expanding test revenues, offset by operational investments in CLIA-certified clinical laboratory facilities in Oxford and Maryland, USA. The company does not currently pay a dividend, maintaining strict overhead controls to extend operational runway as commercial test ordering volumes scale.
Reimbursement Coverage and Upcoming Commercial Milestones
A key operational focus for Oxford BioDynamics (LSE:OBD) is securing insurance reimbursement coverage and CPT coding across US Medicare and private healthcare payors, since institutional reimbursement contracts help remove out-of-pocket costs for patients. Key catalysts over the next twelve months include announcing new commercial coverage determinations from major US health insurers, publishing multi-centre clinical validation data, and reporting full-year audited financial results.
Sector Context and Market Backdrop
Epigenetics examines how DNA is folded and regulated in three dimensions, and these structural patterns can indicate how a person's cells are behaving. The EpiSwitch platform uses this information to build blood-based tests that help to identify disease or predict treatment response. Non-invasive tests are attractive because they can reduce the need for biopsies, and in cancer care they may help clinicians to decide which patients are more likely to benefit from immunotherapy.
What to Watch Next
Readers may follow reimbursement decisions by US insurers, publication of multi-centre clinical validation data and growth in test ordering volumes. Operating laboratories in Oxford and Maryland that meet CLIA standards allows the company to offer tests directly to US clinicians. Updates on the EpiSwitch PSE prostate cancer test and the CiRT immunotherapy response test will show how commercial adoption is developing, and annual results will indicate how revenue is scaling as the focus shifts from R&D to clinical testing.






Please wait processing your request...